CYP19A1 and cancer: Several drugs indicated for cancer treatment presented negative correlations with AD profiles, including the aromatase inhibitor exemestane (r = −0.28) used for the treatment of BRCA, the progestin medication megestrol (r = −0.27), the alkylating agent thiotepa (r = −0.25), tretinoin (r = −0.25), and estradiol (r = −0.24).